| Old Articles: <Older 6261-6270 Newer> |
|---|
 |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.   |
The Motley Fool
March 29, 2010
Brian Orelli |
5 Drugmakers Producing Cash for You Take greenbacks over earnings any day. |
BusinessWeek
March 25, 2010
Elizabeth Lopatto |
And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
The Motley Fool
March 25, 2010
Brian Orelli |
More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services. |
BusinessWeek
March 24, 2010
Nussbaum et al. |
Obamacare's Cost Scalpel How does the health-care overhaul propose to control spending? By evaluating treatments through "comparative effectiveness research" |
Fast Company
April 2010
Gay Jervey |
Fast Talk: The University of Rochester Markets Medical Research Marjorie Hunter markets academic research to companies and entrepreneurs; such collaborations brought the University of Rochester Medical Center nearly $70 million in royalties in fiscal 2008. |
The Motley Fool
March 24, 2010
Matt Koppenheffer |
3 Lowlights of Health-Care Reform It's barreling forward, but what will it do about costs and quality? |
Chemistry World
March 23, 2010 |
Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
| <Older 6261-6270 Newer> Return to current articles. |
